Steven D. Barrett


Co-Chair, Technology Transactions and Licensing Practice Group

Barrett, Steven D.

Steve Barrett, co-chair of the Technology Transactions and Licensing Practice Group, advises a variety of life sciences and technology companies regarding the structuring, negotiation and drafting of agreements for a broad range of technology transactions, including technology acquisition, license, strategic alliance and joint venture transactions, and related research, development, supply, marketing, distribution and services agreements. Mr. Barrett regularly represents entrepreneurs, early-stage and established life sciences and technology companies and large commercial enterprises.

Learn more about Mr. Barrett's practice and how he can support your startup on

Honors & Awards

  • Recognized as a leader in life sciences in the 2015 and 2016 editions of Who's Who Legal
  • Recommended in the 2016 edition of The Legal 500 United States for his work in M&A/Corporate and Commercial as well as Media, Technology and Telecoms: Outsourcing and Transactions
  • Recognized for his practice and named a "Life Sciences Star" in the 2012-2016 editions of LMG Life Sciences
  • Recognized in each edition of the PLC Cross-border Life Sciences Handbook in the USA Commercial and Partnering category since the 2006/07 edition; listed as Leading in this category in the 2009/10 and 2011/12 editions
  • Named "Massachusetts Super Lawyer" in the areas of intellectual property and business/corporate law in the 2014-2016 editions of Boston Magazine
  • Named a "Massachusetts Super Lawyers Rising Star" in intellectual property law in the 2005 and 2006 issues of Boston Magazine

Publications & News


March 16, 2017

Allergan and Editas Medicine Enter Into Strategic R&D Alliance

The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine's unparalleled CRISPR genome editing platform.

February 14, 2017

WilmerHale Counsels Cynosure in $1.65B Acquisition by Hologic

The WilmerHale team on the transaction was led by Hal Leibowitz and Jason Kropp and included Andrew Bonnes, Kim Wethly, Leon Greenfield, Bruce Manheim, Steve Barrett, Laura Schneider, Amy Null, Julie Hogan Rodgers, Ciara Baker, Davis Sluis, Caroline Dotolo and Alex Civetta.

December 23, 2016

WilmerHale Reps Editas Medicine in Licensing of New Technologies

Editas Medicine, Inc., a leading genome editing company, announced it has exclusively licensed intellectual property related to new CRISPR technologies for human therapeutics that will enhance and broaden the range of medicines the company can develop.

December 15, 2016

WilmerHale Reps Spark Therapeutics in Licensing Agreement with Selecta Biosciences

Spark Therapeutics and Selecta Biosciences, Inc. announced a license agreement that provides Spark Therapeutics with exclusive worldwide rights to Selecta's proprietary Synthetic Vaccine Particles platform technology for co-administration with gene therapy targets.

November 9, 2016

LMG Life Sciences Ranks WilmerHale and Attorneys Among the Best

The 2016 supplement highlights nine firm practices and 18 attorneys, recognizing work under three categories—Intellectual Property, Finance and Transactional, and Non-IP Litigation and Enforcement.

October 4, 2016

Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration Agreement

WilmerHale client Summit Therapeutics plc and Sarepta Therapeutics announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States.

June 22, 2016

The Legal 500 United States 2016 Recognizes 111 WilmerHale Lawyers Across 30 Practice Areas

The guide's rankings are based on a series of criteria, including client feedback, interviews with private practice lawyers, and its own research.

December 21, 2015

The Medicines Company Agrees to Divest its Hemostasis Portfolio to Mallinckrodt plc

On December 18, The Medicines Company (NASDAQ:MDCO) announced that it entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company’s global portfolio of three hemostasis products – RECOTHROM® Thrombin topical (Recombinant), PreveLeak™, and RAPLIXA™ (fibrin sealant) – for a total potential consideration of up to $410 million.

September 14, 2015

LMG Life Sciences Release 2015 Rankings, Again Names WilmerHale a "Life Cycle Firm"

In its latest edition, LMG Life Sciences recognizes eight WilmerHale practice areas and 16 attorneys, and for the fourth consecutive year names WilmerHale a "Life Cycle Firm."

March 11, 2015

Thomson Reuters Nominates MacroGenics and Spark Therapeutics for Allicense Breakthrough Alliance Award

WilmerHale is pleased to congratulate clients MacroGenics Inc. and Spark Therapeutics Inc. for having been selected by Thomson Reuters as nominees for the Allicense Breakthrough Alliance Award 2014—an award that honors the creative partnering efforts of business development licensing and M&A professionals.

Recent Highlights

Mr. Barrett has recently represented:

  • Adimab in its antibody platform licensing agreements with GSK (2013), Biogen Idec (2013), Novo Nordisk (2013) and Merck (2015)
  • Agios Pharmaceuticals in its metabolic immuno-oncology collaboration with Celgene (2016)
  • Alnylam in its Asian territory TTR-mediated amyloidosis RNAi collaboration with Genzyme (2012)
  • Alnylam in its prior collaborations with Medtronic (2007), Takeda (2008), Cubist (2009) and GSK (2011)
  • Concert Pharmaceuticals in its multi-program deuterium-modified drug collaboration with Celgene (2013)
  • Concert Pharmaceuticals in its prior collaborations with GSK (2009), Avanir Pharmaceuticals (2012) and Jazz Pharmaceuticals (2013)
  • Dendreon in its $125 million sale of its royalty interest in VICTRELIS™ (boceprevir) to CPPIB Credit Investments (2011)
  • Editas Medicine in its strategic alliance and option agreement with Allergan (2017)
  • Editas Medicine in its licensing of CRISPR technologies from the Broad Institute, MIT, Harvard and other academic institutions (2016)
  • Epizyme in its combination clinical trial collaboration with Genentech (2016)
  • Epizyme in its restructuring of its collaboration with Celgene (2015)
  • Epizyme in its reacquisition of EZH2 inhibitor oncology program rights from Eisai (2015)
  • Epizyme in its prior collaborations with GSK (2011), Eisai (2011), Celgene (2012), Roche Molecular Systems (2012) and Abbott Molecular (2013)
  • Idera Pharmaceuticals in its companion diagnostic development agreement with Abbott Molecular (2014)
  • Lexicon in its worldwide collaboration and licensing agreement for sotagliflozin with Sanofi (2015)
  • Lexicon in its ex-US and Japan licensing agreement for telotristat etiprate with Ipsen (2014)
  • Merrimack Pharmaceuticals in its >$970 million ex-US license and collaboration agreement with Baxter (2014)
  • Merrimack in its prior collaborations with Sanofi-Aventis (2009), PharmaEngine (2011) and Actavis (2013)
  • Mitobridge in its $730 million mitochondria-related disease collaboration with Astellas (2013)
  • Nosocomial Vaccine Corporation in its collaboration with Astellas, Affinivax and University of Maryland (2015)
  • Ophthotech in its >$1 billion ex-US licensing and commercialization agreement for FOVISTA™ with Novartis (2014)
  • Ophthotech in its $175 million royalty financing arrangement with Novo A/S (2013)
  • Potenza Therapeutics in its immuno-oncology collaboration with Astellas (2015)
  • Spark Therapeutics in its synthetic vaccine particles licensing transaction with Selecta Biosciences (2016)
  • Spark Therapeutics in its hemophilia B gene therapy collaboration with Pfizer (2014)
  • Spark Therapeutics in its prior licensing agreements with Genable Technologies (2014) and Children's Hospital of Philadelphia (2013)
  • Summit Therapeutics in its Duchenne muscular dystrophy collaboration with Sarepta Therapeutics (2016)
  • Vertex Pharmaceuticals in its collaboration and licensing agreement to develop ENaC inhibitors for cystic fibrosis and other pulmonary diseases with Parion Sciences (2015)

Community Involvement

Mr. Barrett serves on the board of directors of The Political Asylum/Immigration Representation (PAIR) Project. Mr. Barrett has also successfully represented, on a pro bono basis, a number of persons who have fled persecution in other countries and sought political asylum in the United States.

Mr. Barrett served on active duty as a US naval officer from 1989 to 1992. His assignments included division officer tours in USS Hoel (DGG-13) and USS Waddell (DDG-24), and he qualified as a surface warfare officer and was awarded the Navy Achievement Medal.


Skip Navigation Links.


JD, cum laude, University of Michigan Law School, 1996

MBA, with High Distinction, University of Michigan, 1996

SB, Mechanical Engineering, Massachusetts Institute of Technology, 1989

Bar Admissions



United States Patent and Trademark Office

Skip Navigation Links.